BioCryst Pharmaceuticals (BCRX) Reports Results of Phase 2 Trial on Peramivir
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced results of an exploratory Phase 2 trial of intravenous peramivir, a neuraminidase inhibitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
